Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.52 |
| ▸ | AKT2 | P31751 | 20/20 | 0.52 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131053 | 1.00 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3664890 | 1.00 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3401639 | 1.00 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL12194050 | 0.85 | AKT1 (0.53) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16488547 | 0.83 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16488551 | 0.83 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16488554 | 0.83 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL22533529 | 0.81 | AKT1 (0.50) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL21919545 | 0.81 | AKT1 (0.50) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3122777 | 0.81 | AKT1 (0.50) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694073-A1 | COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE | Genentech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694071-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694485-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | Genentech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2694072-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE | Genentech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012135759-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135781-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135779-A1 | COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135750-A1 | COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND VEMURAFENIB, AND METHODS OF USE | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-2049500-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049501-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008006032-A1 | CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008006040-A1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |